It's National Immunization Awareness Month! The initial signs and symptoms of whooping cough are easy to mistake for symptoms of the common cold. Later stages, however, may be more severe and have a long-term impact on those infected. Diasorin offers targeted and flexible panel testing options to help clinicians distinguish between whooping cough and similarly presenting respiratory illnesses. Explore our full respiratory testing menu to see how our flexible testing options can help your lab provide the right test for the right patient at the right time: https://hubs.li/Q02H8Ptt0 #DiasorinMolecular #ImmunizationAwareness #DiagnosticStewardship #WhoopingCough #StayInformed
Chi siamo
DiaSorin is an Italian multinational group, one of the leading hi-tech players in the in vitro diagnostics market and, in particular, in the immunodiagnostics and molecular diagnostics segments, with over 50 years of experience. Our Group, owned by DiaSorin S.p.A., consists of 24 Companies, 5 foreign branches, offices on the 5 Continents and 6 manufacturing facilities located in Italy, Germany, UK, USA and South Africa. We are present in more than 60 countries with our direct sales network, supported by an international network of over 100 independent distributors. We develop, manufacture and market a vast and innovative line of tests for the diagnosis of infectious diseases or hormonal disorders, specifically designed for hospital and private testing laboratories, with an offer embracing different clinical areas. With more than 2000 employees all over the world, and over 210 researchers, we focus our business on improving the health and quality of people’s lives, through high-quality diagnostic products. We count on everyone’s uniqueness, with their skill and talent sets, and it’s considered a fundamental element for the creation of a working environment of excellence, able to adapt to the needs of a constantly evolving market.
- Sito Web
-
http://www.diasorin.com/
Link esterno per DiaSorin
- Settore
- Ricerca biotecnologica
- Dimensioni dell’azienda
- 1001 - 5000 dipendenti
- Sede principale
- Saluggia, VC
- Tipo
- Società privata non quotata
- Settori di competenza
- Healthcare, Biotechnology, In Vitro Diagnostic, Immunoassay, Molecular Diagnostic, Blood tests, GI Stool Testing, Vitamin D, Prenatal screening, Infectious Diseases e Life Science
Località
-
Principale
Ottieni indicazioni
Via Crescentino
Saluggia, VC 13040, IT
-
Ottieni indicazioni
11331 Valley View St
Cypress, California, California 90630-4717, US
-
Ottieni indicazioni
1951 Northwestern Avenue PO BOX 285
Stillwater, Minnesota 55082 - 0285, US
-
Ottieni indicazioni
12212 Technology Blvd
Austin, Texas 78727, US
Dipendenti presso DiaSorin
-
Riccardo Fava
Corporate VP @ Diasorin | Corporate Communications, ESG & Investor Relations
-
Jesse Nergard
Innovator in Global Talent Acquisition: Pioneering the Future of the Biotech Workforce 🌌
-
Michael Howachyn
-
Rodrigo Pellicciari
Global Sales & Commercial Operations Executive
Aggiornamenti
-
It's time to stand united and fight TB. 💪🏻 Together, we can make a difference. Join the Global TB Summit.
🙌 Last year was a success, and we're taking it up a notch! Latest tuberculosis (TB) research, inspiring stories and powerful connections await at the Global #TB Summit 2024. Register now for free 👉https://lnkd.in/e3XXEJzg Get ready to: ✅ Learn from 35+ global TB experts ✅ Network with thousands of TB advocates ✅ Be inspired by powerful stories from TB survivors ✅ Earn CPD and CME credits #globalTBsummit #TBevent #tuberculosis
-
Diasorin offers an Analyte Specific Reagent (ASR) primer pair that detects the B17R/B18R gene of the mpox virus, responsible for the ongoing global public health concern. The ASR can be used by high complexity clinical laboratories to develop and validate assays to detect mpox virus DNA for diagnostic purposes as well as by non-clinical laboratories to develop and validate tests for research, forensic, and other non-clinical purposes. Read more: https://hubs.li/Q02M6MP-0
-
-
The recent upsurge of mpox within parts of Africa has evolved into an international public health concern according to the World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus. Noting the latest emergence of an mpox new clade, Dr. Tedros said that "a coordinated international response is needed to stop these outbreaks and save lives."
WHO Director-General Dr Tedros Adhanom Ghebreyesus has determined that the upsurge of mpox in the Democratic Republic of the Congo (DRC) and a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC) under the International Health Regulations (2005). Read the press release: https://bit.ly/3Aybiq4
-
-
We are grateful for BARDA's support in bringing the improved NxTAG product—NxTAG RPP v2—to market.
The NxTAG Respiratory Pathogen Panel v2, a combination test from partner Diasorin that was developed with BARDA support, recently received FDA 510(k) clearance. This improved multiplexed PCR test detects 21 common viral and bacterial pathogens that cause respiratory illness, including COVID-19. With this test, clinicians will be able to rapidly detect and differentiate among the most common pathogens that cause respiratory illness and provide life-saving treatment to patients. This latest clearance supports national preparedness by leveraging existing platforms that can be rapidly adapted to emerging threats. Learn more: https://ow.ly/7fSX50SYtW3
-
-
It's National Immunization Awareness Month! Did you know that the symptoms of whooping cough can look like the common cold in its early stages? Whooping cough is a dangerous and potentially deadly illness, particularly for babies under one year of age. Fortunately, a vaccine is available for this highly contagious respiratory illness and is recommended by the CDC for all babies to greatly reduce risk of developing infection. For those that are suspected of having an infection, our targeted and flexible testing options allow you to test purpose and treat with precision to support your patient testing needs: https://hubs.li/Q02H8MY60 #DiasorinMolecular #ImmunizationAwareness #DiagnosticStewardship #WhoopingCough #StayInformed
-
-
We’re excited to share that we’re making significant strides in supporting clinical laboratories worldwide! Our LIAISON® XL series is gaining momentum, and we’re nearing a remarkable production milestone. This growing demand is a testament to our customers' trust in us to deliver reliable, efficient, and innovative solutions for specialty testing. Stay tuned for an exciting update as we celebrate this important achievement! #LIAISONXL #laboratoryautomation #clinicaldiagnostics #healthcareinnovation #patientcare
-
-
Thank you for stopping by Diasorin booth # 1424 at ADLM 2024 and meeting with our Diasorin and Luminex experts. We hope you walked away with new ways to accelerate your diagnostic stewardship initiatives and learned how you can achieve a competitive edge with our xMAP® Multiplexing Technology. Missed the show or just want to learn more about our products, please visit our website: https://hubs.li/Q02JQb_T0 We’ll see you back in Chicago next year! #ADLM #xMAPTechnology #diagnosticstewardship #fungalinfections #emergingdiseases #differentialtesting #lifesciences #diagnostictesting #immunodiagnostictesting
-
-
We hope you enjoyed our in-booth presentations yesterday about real world applications of xMAP® Technology, LIAISON® MeMed BV®,learning about emerging fungal threats and the importance of flexible testing. Missed any of the presentations yesterday? We will be re-presenting 3 of them at booth # 1424, as well as a new one about strategies for implementing clinician advocates. Wednesday, July 31st 10 AM “Diagnostic Stewardship for Syndromic Respiratory Testing: Flexibility is the Name of the Game” with Kaisha Gonzalez, PhD 11 AM “Loyola University Medical Center real-world experience with the FDA-approved LIAISON® MeMed BV®” with Mark E Cichon, DO and David M Engman, MD, PhD 2 PM “Strategies for Enlisting Clinician Advocates for a New FDA-Approved Diagnostic Test: Lessons from LIAISON® MeMed BV®” with Dr. David Engman, MD, PhD 3 PM “Candida auris: An Emerging Threat to Public Health and the First FDA De Novo Granted Molecular Assay for Identifying At-Risk Patients” with Michelle Tabb, PhD Learn more about our comprehensive suite of products: https://hubs.li/Q02JyCbF0 #ADLM #xMAPTechnology #diagnosticstewardship #fungalinfections #emergingdiseases #differentialtesting #lifesciences #diagnostictesting #immunodiagnostictesting
-
-
The ADLM 2024 floor is open! Discover your next solution to support your diagnostic stewardship goals or learn how you can achieve a competitive edge with our xMAP® Multiplexing Technology at booth #1424. Interested in learning more? Stay a while for our in-booth presentations: Tuesday, July 30th 10 AM “Advancing translational research using xMAP® Multiplexing Technology: Real-World Applications” with Dr. Gabriela Garcia-Soto, PhD 11 AM “Loyola University Medical Center real-world experience with the FDA-approved LIAISON® MeMed BV®” with Mark E Cichon, DO and David M Engman, MD, PhD 2 PM “Candida auris: An Emerging Threat to Public Health and the First FDA De Novo Granted Molecular Assay for Identifying At-Risk Patients” with Michelle Tabb, PhD 3 PM “Diagnostic Stewardship for Syndromic Respiratory Testing: Flexibility is the Name of the Game” with Kaisha Gonzalez, PhD Learn more about our comprehensive suite of products here: https://hubs.li/Q02JpLgw0 #ADLM #xMAPTechnology #diagnosticstewardship #fungalinfections #emergingdiseases #differentialtesting #lifesciences
-